A Phase 1, Open-label, Randomized, 3-period, 3-sequence, Single-dose Crossover Bioavailability and Food Effect Study of SACT-1 (Rilpivirine Suspension) and Edurant® Tablets in Healthy Adult Volunteers
Latest Information Update: 29 Nov 2022
At a glance
- Drugs SACT 1 (Primary) ; Rilpivirine
- Indications Colorectal cancer; Neuroblastoma; Triple negative breast cancer
- Focus First in man; Pharmacokinetics
- Sponsors Aptorum Group
- 02 May 2022 According to an Aptorum Group media release, this study was conducted by an independent clinical contract research organization.
- 02 May 2022 Results presented in an Aptorum Group Media Release.
- 10 Jan 2022 According to an Aptorum Group media release, the company has completed this study.